ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Mental Health
The Case Against Antidepressants
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="FunkOdyssey" data-source="post: 232732" data-attributes="member: 44064"><p>This paper provides further evidence that relapses in antidepressant relapse prevention trials are caused by a pharmacological drug effect and are not indicative of antidepressants' prophylactic power. This one has some cool graphs that [USER=38590]@readalot[/USER] will appreciate -- click the full-text link at the bottom to check those out:</p><p></p><p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361519/#" target="_blank">Ther Adv Psychopharmacol.</a> 2021; 11: 20451253211032051.</p><p>Published online 2021 Aug 10. doi: <a href="https://doi.org/10.1177%2F20451253211032051" target="_blank">10.1177/20451253211032051</a></p><h3>Prophylactic effects or withdrawal reactions? An analysis of time-to-event data from antidepressant relapse prevention trials submitted to the FDA</h3><p><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Hengartner%20MP%5BAuthor%5D" target="_blank">Michael P. Hengartner</a> and <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Pl%C3%B6derl%20M%5BAuthor%5D" target="_blank">Martin Plöderl</a></p><h3>Abstract</h3><h4><strong>Background:</strong></h4><p>Relapse prevention trials build the scientific foundation for recommendation of antidepressant continuation and maintenance therapy. However, the validity of the evidence is disputed and may be biased due to withdrawal confounding.</p><h4><strong>Methods:</strong></h4><p>We analysed survival curves from all antidepressant relapse prevention trials submitted to the United States (US) Food and Drug Administration (FDA) between 1987 and 2012 for 13 approved drugs. The main outcome was the percent of the drug effect (placebo-antidepressant difference in relapse events) at any week of the maintenance phase in relation to the total drug effect at the endpoint of the randomised maintenance phase.</p><h4><strong>Results:</strong></h4><p>Altogether, 14 studies with a mean observation period of 38.9 weeks (Kaplan–Meier estimators) were analysed. At week 3, a mean of 20.6% [95% confidence interval (CI) = 10.9–30.3%] of the total drug effect was achieved. At weeks 6 and 12, the corresponding figures were 50.3% (37.3–63.3%) and 69.0% (55.1–82.8%). No further antidepressant–placebo separation was observed as of week 24 [101.0% of total drug effect (94.6–107.3%)]. This means that censoring relapse events that occurred in the first 3, 6, 12 and 24 weeks would reduce the total drug effect at study endpoint by 20.6%, 50.3%, 69.0% and 101.0%, respectively. Assuming antidepressants had a constant prophylactic effect over 38.9 weeks, we further showed that, around week 6, the antidepressant–placebo separation was about three times larger than expected.</p><h4><strong>Conclusion:</strong></h4><p>The placebo–antidepressant separation was disproportionally large between weeks 3 and 6 of the randomised maintenance phase. The benefits of continuing antidepressants relative to abrupt/rapid discontinuation declined sharply after week 6. This indicates an excess of relapse events in the placebo arms during the early maintenance phase that may be due to withdrawal reactions caused by abrupt/rapid discontinuation of active treatment. If these early relapse events are due to a direct pharmacological effect, then antidepressants’ true prophylactic long-term effects are substantially overestimated.</p><p></p><p>[URL unfurl="true"]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361519/[/URL]</p></blockquote><p></p>
[QUOTE="FunkOdyssey, post: 232732, member: 44064"] This paper provides further evidence that relapses in antidepressant relapse prevention trials are caused by a pharmacological drug effect and are not indicative of antidepressants' prophylactic power. This one has some cool graphs that [USER=38590]@readalot[/USER] will appreciate -- click the full-text link at the bottom to check those out: [URL='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361519/#']Ther Adv Psychopharmacol.[/URL] 2021; 11: 20451253211032051. Published online 2021 Aug 10. doi: [URL='https://doi.org/10.1177%2F20451253211032051']10.1177/20451253211032051[/URL] [HEADING=2]Prophylactic effects or withdrawal reactions? An analysis of time-to-event data from antidepressant relapse prevention trials submitted to the FDA[/HEADING] [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Hengartner%20MP%5BAuthor%5D']Michael P. Hengartner[/URL] and [URL='https://pubmed.ncbi.nlm.nih.gov/?term=Pl%C3%B6derl%20M%5BAuthor%5D']Martin Plöderl[/URL] [HEADING=2]Abstract[/HEADING] [HEADING=3][B]Background:[/B][/HEADING] Relapse prevention trials build the scientific foundation for recommendation of antidepressant continuation and maintenance therapy. However, the validity of the evidence is disputed and may be biased due to withdrawal confounding. [HEADING=3][B]Methods:[/B][/HEADING] We analysed survival curves from all antidepressant relapse prevention trials submitted to the United States (US) Food and Drug Administration (FDA) between 1987 and 2012 for 13 approved drugs. The main outcome was the percent of the drug effect (placebo-antidepressant difference in relapse events) at any week of the maintenance phase in relation to the total drug effect at the endpoint of the randomised maintenance phase. [HEADING=3][B]Results:[/B][/HEADING] Altogether, 14 studies with a mean observation period of 38.9 weeks (Kaplan–Meier estimators) were analysed. At week 3, a mean of 20.6% [95% confidence interval (CI) = 10.9–30.3%] of the total drug effect was achieved. At weeks 6 and 12, the corresponding figures were 50.3% (37.3–63.3%) and 69.0% (55.1–82.8%). No further antidepressant–placebo separation was observed as of week 24 [101.0% of total drug effect (94.6–107.3%)]. This means that censoring relapse events that occurred in the first 3, 6, 12 and 24 weeks would reduce the total drug effect at study endpoint by 20.6%, 50.3%, 69.0% and 101.0%, respectively. Assuming antidepressants had a constant prophylactic effect over 38.9 weeks, we further showed that, around week 6, the antidepressant–placebo separation was about three times larger than expected. [HEADING=3][B]Conclusion:[/B][/HEADING] The placebo–antidepressant separation was disproportionally large between weeks 3 and 6 of the randomised maintenance phase. The benefits of continuing antidepressants relative to abrupt/rapid discontinuation declined sharply after week 6. This indicates an excess of relapse events in the placebo arms during the early maintenance phase that may be due to withdrawal reactions caused by abrupt/rapid discontinuation of active treatment. If these early relapse events are due to a direct pharmacological effect, then antidepressants’ true prophylactic long-term effects are substantially overestimated. [URL unfurl="true"]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361519/[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Mental Health
The Case Against Antidepressants
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top